Correlation Between Aerovate Therapeutics and 126408HH9

Can any of the company-specific risk be diversified away by investing in both Aerovate Therapeutics and 126408HH9 at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aerovate Therapeutics and 126408HH9 into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Aerovate Therapeutics and CSX P 325, you can compare the effects of market volatilities on Aerovate Therapeutics and 126408HH9 and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aerovate Therapeutics with a short position of 126408HH9. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aerovate Therapeutics and 126408HH9.

Diversification Opportunities for Aerovate Therapeutics and 126408HH9

-0.62

Correlation Coefficient

Aerovate Therapeutics  126408HH9

Excellent diversification

The 3 months correlation between Aerovate and 126408HH9 is -0.62. Overlapping area represents the amount of risk that can be diversified away by holding Aerovate Therapeutics and CSX P 325 in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CSX P 325 and Aerovate Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aerovate Therapeutics are associated (or correlated) with 126408HH9. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CSX P 325 has no effect on the direction of Aerovate Therapeutics i.e., Aerovate Therapeutics and 126408HH9 go up and down completely randomly.

Pair Corralation between Aerovate Therapeutics and 126408HH9

Given the investment horizon of 90 days Aerovate Therapeutics is expected to generate 4.92 times more return on investment than 126408HH9. However, Aerovate Therapeutics is 4.92 times more volatile than CSX P 325. It trades about 0.01 of its potential returns per unit of risk. CSX P 325 is currently generating about -0.18 per unit of risk. If you would invest  253.00  in Aerovate Therapeutics on September 18, 2024 and sell it today you would earn a total of  0.50  from holding Aerovate Therapeutics or generate 0.2% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Aerovate Therapeutics  vs.  CSX P 325

Aerovate Therapeutics

Risk-Adjusted Performance

11 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Aerovate Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of rather inconsistent basic indicators, Aerovate Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.

CSX P 325

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days CSX P 325 has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, 126408HH9 is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Aerovate Therapeutics and 126408HH9

The main advantage of trading using opposite Aerovate Therapeutics and 126408HH9 positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aerovate Therapeutics position performs unexpectedly, 126408HH9 can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in 126408HH9 will offset losses from the drop in 126408HH9's long position.

The idea behind Aerovate Therapeutics and CSX P 325 pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.